To review the role of statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) in the prevention and treatment of Alzheimer's disease (AD).
Data Sources:
Literature was retrieved from EMBASE (1980–2010, week 22) and MEDLINE (1950-May 2010, week 4), using the key words statins, HMG-CoA reductase inhibitors, and Alzheimer's disease, as well as a bibliographic review of published articles.
Study Selection and Data Extraction:
All clinical trials that involved humans, were published in the English language, and evaluated statins in the prevention and/or treatment of AD were included in this review.
Data Synthesis:
Recent studies have evaluated the use of statins in the prevention and treatment of AD; results from these studies are conflicting. One randomized, placebo-controlled trial found that statins may improve the ADAS-Cog (Alzheimer's Disease Assessment Scale on Cognition) by 0.1–1.8 points in patients with AD during the first 6 months of treatment. Alternatively, another randomized controlled trial found that atorvastatin did not provide benefit on the ADAS-Cog. Although many of the prevention trials did find potential benefit with statin use, these trials were observational.
Conclusions:
Due to insufficient evidence of benefit in both the prevention and treatment of AD, statins cannot be recommended at this time.
QaseemASnowVCrossJTJr. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med2008; 148: 370–8.
3.
GrossbergGTDesaiAK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci2003; 58: 331–53.
APA Work Group on Alzheimer's Disease and other Dementias, RabinsPVBlackerDRovnerBW. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. 2nd ed.Am J Psychiatry2007; 164: 5–56.
6.
LleoAGreenbergSMGrowdonJH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med2006; 57: 513–33.
7.
LyketsosCGColendaCCBeckC. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry2006; 14: 561–72.
8.
SimonsMKellerPDe StrooperBBeyreutherKDottiCGSimonsK. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A1998; 95: 6460–4.
9.
LaneRMFarlowMR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res2005; 46: 949–68.
10.
PackardCJWestendorpRGStottDJ. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc2007; 55: 1777–85.
11.
CorsiniABellostaSBaettaRFumagalliRPaolettiRBerniniF. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther1999; 84: 413–28.
12.
HamelinBATurgeonJ. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci1998; 19: 26–37.
13.
WolozinBKellmanWRuosseauPCelesiaGGSiegelG. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol2000; 57: 1439–43.
14.
HajjarISchumpertJHirthVWielandDEleazerGP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci2002; 57: M414–8.
15.
ZamriniEMcGwinGRosemanJM. Association between statin use and Alzheimer's disease. Neuroepidemiology2004; 23: 94–8.
16.
GreenRCMcNagnySEJayakumarP. Statin use and the risk of Alzheimer's disease: The MIRAGE study. Alzheimers Dement2006; 2: 96–103.
17.
SparksDLKryscioRJSabbaghMNConnorDJSparksLMLiebsackC. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res2008; 5: 416–21.
18.
RockwoodKKirklandSHoganDB. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol2002; 59: 223–7.
19.
LiGHigdonRKukullWA. Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology2004; 63: 1624–8.
20.
DufouilCRichardFFievetN. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study. Neurology2005; 64: 1531–8.
21.
ReaTDBreitnerJCPsatyBM. Statin use and the risk of incident dementia: The cardiovascular health study. Arch Neurol2005; 62: 1047–51.
22.
ZandiPPSparksDLKhachaturianAS. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry2005; 62: 217–24.
23.
ArvanitakisZSchneiderJAWilsonRS. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology2008; 70: 1795–1802.
24.
HaagMDHofmanAKoudstaalPJStrickerBHBretelerMM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry2009; 80: 13–7.
25.
JacobsonTA. Overcoming ‘ageism’ bias in the treatment of hypercholesterolaemia: A review of safety issues with statins in the elderly. Drug Saf2006; 29: 421–48.
26.
BarryPJGallagherPRyanCO'MahonyD. START (Screening Tool to Alert Doctors to the Right Treatment)—an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing2007; 36: 632–8.
27.
SjogrenMGustafssonKSyversenS. Treatment with sim-vastatin in patients with Alzheimer's disease lowers both alpha-and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord2003; 16: 25–30.
28.
SimonsMSchwarzlerFLutjohannD. Treatment with sim-vastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol2002; 52: 346–50.
29.
SparksDLSabbaghMNConnorDJ. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res2005; 2: 343–53.
30.
FeldmanHHDoodyRSKivipeltoM. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology2010; 74: 956–64.
31.
WinbladBJelicVKershawPAmatniekJ. Effects of statins on cognitive function in patients with Alzheimer's disease in galan-tamine clinical trials. Drugs Aging2007; 24: 57–61.
32.
SparksDLSabbaghMNConnorDJ. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol2005; 62: 753–7.
33.
SparksDLConnorDJSabbaghMNPetersenRBLopezJBrowneP. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl2006; 185: 3–7.
34.
ShumakerSALegaultCRappSR. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory study: A randomized controlled trial. JAMA2003; 289: 2651–2.
35.
de la TorreJC. The vascular hypothesis of Alzheimer's disease: Bench to bedside and beyond. Neurodegener Dis2010; 7: 116–21.
36.
LuzziSVellaLBartoliniMProvincialiLSilvestriniM. Atherosclerosis in the evolution of Alzheimer's disease: Can treatment reduce cognitive decline?J Alzheimers Dis2010; 20: 893–901.
37.
ArmitageJ. The safety of statins in clinical practice. Lancet2007; 370: 1781–90.
